Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes

被引：0
|
作者：
Horowitz, M. [1 ]
Flint, A. [2 ]
Doran, S.
Rasmussen, M. F. [2 ]
Kapitza, C. [3 ]
Andreasen, A. H. [2 ]
Jones, K. L. [1 ]
Zdravkovic, M. [2 ]
Chapman, I. M. [1 ]
机构：
[1] Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[3] Profil Inst Stoffwechselforsch GmbH, Neuss, Germany
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
889
引用
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
  • [1] Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
    Horowitz, Michael
    Flint, Anne
    Jones, Karen L.
    Hindsberger, Charlotte
    Rasmussen, Mads F.
    Kapitza, Christoph
    Doran, Selena
    Jax, Thomas
    Zdravkovic, Milan
    Chapman, Ian M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (02) : 258 - 266
  • [2] The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
    Flint, A.
    Kapitza, C.
    Zdravkovic, M.
    DIABETES OBESITY & METABOLISM, 2013, 15 (10): : 958 - 962
  • [3] Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
    Vilsboll, Tina
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (02) : 231 - 237
  • [4] The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake
    Flint, Anne
    Kapitza, Christoph
    Hinds-Berger, Charlotte
    Zdravkovic, Milan
    DIABETES, 2008, 57 : A165 - A165
  • [5] Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes
    Ryan, Gina J.
    Hardy, Yolanda
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (03) : 260 - 274
  • [6] The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol
    Kapitza, Christoph
    Flint, Anne
    Hindsberger, Charlotte
    Zdravkovic, Milan
    DIABETES, 2008, 57 : A593 - A593
  • [7] Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
    Russell-Jones, David
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 297 (1-2) : 137 - 140
  • [8] Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
    Seino, Y.
    Rasmussen, M. F.
    Nishida, T.
    Kaku, K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1013 - 1022
  • [9] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
    Horowitz, M.
    Vilsboll, T.
    Zdravkovic, M.
    Hammer, M.
    Madsbad, S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
  • [10] Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride
    Bode, B. W.
    Hale, P. M.
    Hammer, M.
    Testa, M. A.
    Garber, A.
    DIABETOLOGIA, 2008, 51 : S357 - S358
12345